Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
Invicro
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy with no clinically relevant finding on physical examination at screening and prior to radiopharmaceutical administration
Female participants must be willing to avoid pregnancy and refrain from donating eggs during the treatment period and for 30 days after the final dose
Male participants with partners of childbearing potential must commit to the use of two methods of contraception for the study duration and 90 days after the last dose
Male participants must not donate sperm for the duration of the study and 90 days after the last dose
Participants must have both Japanese parents and all Japanese grandparents
You may not be if
Participants with any significant medical disorder or disease expected to interfere with the study
Current or prior history (within a six-month period) of exposure to nicotine products
History of drug or alcohol abuse within 12 months prior to screening
Prior participation in other research protocols or clinical care in the last year, such that radiation exposure combined with that from the present study exceeds an effective dose of 50 millisievert (mSv), the allowable annual limit for research participants as established by the US Federal Guidelines
Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial dosing
Use of over the counter (OTC) medication, dietary supplements, or vitamins, within 2 weeks prior to initial dosing
Known hypersensitivity to any component of the formulation of \[18F\]GTP1 or related compounds
Major surgery, or donation or loss of 400 mL or more of blood within 4 weeks prior to initial dosing
History of immunodeficiency diseases, including positive human immunodeficiency virus (HIV) test
Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody
Women who are pregnant, lactating or breastfeeding
